11 Companies Launch Biosimilars Forum
- By BSTQ Staff
In May, the Biosimilars Forum was launched by 11 of the leading biosimilar developers in the U.S.: Actavis, Amgen, Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Hospira, Merck, Pfizer, Samsung, Sandoz and Teva. According to a press release, “The forum will provide evidence-based information to educate and advocate for public policies and practices that encourage access, awareness and adoption of biosimilars. The officials who will lead the forum include (president) Juliana Reed, vice-president, Global Government Affairs, Hospira; (vice president) Hillel Cohen, PhD, executive director, Scientific Affairs, Sandoz Biopharmaceuticals (a Novartis company); (treasurer) Geoffrey Eich, executive director, External Affairs, Amgen Biosimilars; and (secretary) Stacie Phan, director, State Government Affairs and Public Policy, Boehringer Ingelheim. The forum submitted a public statement to the Centers for Medicare and Medicaid Services Healthcare Common Procedure Coding System to address the need for appropriate coding for biosimilars.
